For example, although DDX21 is highly expressed in breast cancer (131), colorectal cancer (89), gastric cancer (132) and neuroblastoma (90), low DDX21 levels are associated with poor clinical outcome of breast cancer patients (91). This evidence concerns the gene DDX21 and neuroblastoma.